Literature DB >> 12502361

Homology modeling of rat and human cytochrome P450 2D (CYP2D) isoforms and computational rationalization of experimental ligand-binding specificities.

Jennifer Venhorst1, Antonius M ter Laak, Jan N M Commandeur, Yoshihiko Funae, Toyoko Hiroi, Nico P E Vermeulen.   

Abstract

The ligand-binding characteristics of rat and human CYP2D isoforms, i.e., rat CYP2D1-4 and human CYP2D6, were investigated by measuring IC(50) values of 11 known CYP2D6 ligands using 7-methoxy-4-(aminomethyl)coumarin (MAMC) as substrate. Like CYP2D6, all rat CYP2D isozymes catalyzed the O-demethylation of MAMC with K(m) and V(max) values ranging between 78 and 145 microM and 0.048 and 1.122 min(-1), respectively. To rationalize observed differences in the experimentally determined IC(50) values, homology models of the CYP2D isoforms were constructed. A homology model of CYP2D6 was generated on the basis of crystallized rabbit CYP2C5 and was validated on its ability to reproduce binding orientations corresponding to metabolic profiles of the substrates and to remain stable during unrestrained molecular dynamics simulations at 300 K. Twenty-two active site residues, sharing up to 59% sequence identity, were identified in the CYP2D binding pockets and included CYP2D6 residues Phe120, Glu216, and Asp301. Electrostatic potential calculations displayed large differences in the negative charge of the CYP2D active sites, which was consistent with observed differences in absolute IC(50) values. MD studies on the binding mode of sparteine, quinidine, and quinine in CYP2D2 and CYP2D6 furthermore concurred well with experimentally determined IC(50) values and metabolic profiles. The current study thus provides new insights into differences in the active site topology of the investigated CYP2D isoforms.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12502361     DOI: 10.1021/jm0209578

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  14 in total

1.  Integrating computational and mixture-based screening of combinatorial libraries.

Authors:  Austin B Yongye; Clemencia Pinilla; Jose L Medina-Franco; Marc A Giulianotti; Colette T Dooley; Jon R Appel; Adel Nefzi; Thomas Scior; Richard A Houghten; Karina Martínez-Mayorga
Journal:  J Mol Model       Date:  2010-09-21       Impact factor: 1.810

Review 2.  Predicting the oxidative metabolism of statins: an application of the MetaSite algorithm.

Authors:  Giulia Caron; Giuseppe Ermondi; Bernard Testa
Journal:  Pharm Res       Date:  2007-03       Impact factor: 4.200

3.  Using a homology model of cytochrome P450 2D6 to predict substrate site of metabolism.

Authors:  Rayomand J Unwalla; Jason B Cross; Sumeet Salaniwal; Adam D Shilling; Louis Leung; John Kao; Christine Humblet
Journal:  J Comput Aided Mol Des       Date:  2010-04-02       Impact factor: 3.686

4.  Inhibition of Hepatic CYP2D6 by the Active N-Oxide Metabolite of Sorafenib.

Authors:  Michael Murray; Tina B Gillani; Tristan Rawling; Pramod C Nair
Journal:  AAPS J       Date:  2019-10-21       Impact factor: 4.009

Review 5.  Molecular docking: a powerful approach for structure-based drug discovery.

Authors:  Xuan-Yu Meng; Hong-Xing Zhang; Mihaly Mezei; Meng Cui
Journal:  Curr Comput Aided Drug Des       Date:  2011-06       Impact factor: 1.606

6.  Antidotes to anthrax lethal factor intoxication. Part 2: structural modifications leading to improved in vivo efficacy.

Authors:  Seongjin Kim; Guan-Sheng Jiao; Mahtab Moayeri; Devorah Crown; Lynne Cregar-Hernandez; Linda McKasson; Stephen A Margosiak; Stephen H Leppla; Alan T Johnson
Journal:  Bioorg Med Chem Lett       Date:  2011-02-18       Impact factor: 2.823

Review 7.  Insights into drug metabolism by cytochromes P450 from modelling studies of CYP2D6-drug interactions.

Authors:  J-D Maréchal; C A Kemp; G C K Roberts; M J I Paine; C R Wolf; M J Sutcliffe
Journal:  Br J Pharmacol       Date:  2007-11-19       Impact factor: 8.739

8.  Pharmacokinetics of mirtazapine and its main metabolites after single intravenous and oral administrations in rats at two dose rates.

Authors:  Mohammad-Reza Rouini; Hoda Lavasani; Behjat Sheikholeslami; Helen Owen; Mario Giorgi
Journal:  Daru       Date:  2014-01-07       Impact factor: 3.117

9.  Modelling species selectivity in rat and human cytochrome P450 2D enzymes.

Authors:  Grace H C Edmund; David F V Lewis; Brendan J Howlin
Journal:  PLoS One       Date:  2013-05-14       Impact factor: 3.240

Review 10.  Recent Trends and Applications of Molecular Modeling in GPCR⁻Ligand Recognition and Structure-Based Drug Design.

Authors:  Xiaojing Yuan; Yechun Xu
Journal:  Int J Mol Sci       Date:  2018-07-20       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.